Opto Circuits gets USFDA clearance for its eVision patient-monitoring system

The US Food and Drug Administration (USFDA) yesterday granted its approval for the new modular patient monitoring system eVision 9100 manufactured by Criticare Systems Inc, a wholly owned US subsidiary of Opto Circuits (India) Limited (OCI).

The certification enables Criticare to market and commercially distribute eVision 9100 in the US and most parts of the world, a statement said.

OCI chairman and managing director Vinod Ramnani commented, ''US FDA clearance will now enable us to commercialise eVision 9100 in the US and will help boost sales in other parts of the world.''

Bengaluru-based OCI is a leading Indian developer and manufacturer of patient monitoring systems. Its products include digital thermometers, sensors, pulse oximeters, patient monitoring systems, gas analysers, stents, and catheters.

The company has 13 subsidiaries and reported a consolidated turnover of Rs1,077 crore in FY2010. Its key markets are in the US, Europe and Asia.
In 2008, OCI acquired Wisconsin-based Criticare, also a developer and manufacturer of patient monitoring systems and accessories used in anaesthesia, critical care, medical transport, outpatient care etc.

The new eVision 9100 is the first modular 'green' environmentally friendly monitor, which includes a trickle charge solar panel. The plug-and-play monitor measures physiological parameters of patients that can be removed or changed without interruptions to the operating system, and it also includes Criticare's patented water trap system.